A5090469515- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Hemoglobinopathies and Related Disorders
- Cytokine Signaling Pathways and Interactions
- Eosinophilic Disorders and Syndromes
- Prenatal Screening and Diagnostics
- Acute Myeloid Leukemia Research
- Blood groups and transfusion
- Bone and Joint Diseases
- Abdominal Trauma and Injuries
- Nanoparticle-Based Drug Delivery
- Retinoids in leukemia and cellular processes
- Autoimmune and Inflammatory Disorders Research
- Renal Transplantation Outcomes and Treatments
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- RNA Interference and Gene Delivery
- Kruppel-like factors research
Agostino Gemelli University Polyclinic
2021-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2021-2024
Università Cattolica del Sacro Cuore
2021-2024
Catholic University of America
2022-2023
Arterial (AT) and venous (VT) thrombotic events are the most common complications in patients with polycythemia vera (PV) leading causes of morbidity mortality. In this regard, impact JAK2V617F variant allele frequency (VAF) is still debated. The purpose current study was to analyze VAF context other established risk factors for thrombosis a total 865 2016 WHO-defined PV utilizing two independent cohorts: University Florence (n = 576) as training cohort Policlinico Gemelli, Catholic...
The current retrospective study involving a total of 1607 patients was designed to identify clinical and molecular variables that were predictive inferior myelofibrosis-free survival (MFS) in WHO-defined essential thrombocythemia (ET), utilizing three independent patient cohorts: University Florence, Italy (n = 718); Mayo Clinic, USA 479) Policlinico Gemelli, Catholic University, Rome, 410). Florence cohort first examined risk factors for MFS, which included age > 60 years (HR 2.5, 95% CI...
In polycythemia vera (PV), the prognostic relevance of an ELN-defined complete response (CR) to hydroxyurea (HU), predictors response, and patients’ triggers for switching ruxolitinib are uncertain. a real-world analysis, we evaluated their impact on clinical outcomes CR HU, correlations between partial or no (PR/NR) patient ruxolitinib. Among 563 PV patients receiving HU ≥12 months, 166 (29.5%) achieved CR, 264 PR, 133 NR. multivariate absence splenomegaly (p = 0.03), pruritus 0.002),...
Introduction Indications for HSCT are increasing worldwide, paralleled by a growing demand donors of therapeutic cells. Methods Herein, we report our real-world experience adult HPC donor assessment during 5-year study period (2018–2023): have retrospectively revised data 455 potential related stem cell donors, consecutively evaluated at center. Donor medical history was assessed questionnaire and an interview with trained physician experienced in donation procedures to evaluate fitness...
Splenomegaly is a common manifestation in chronic lymphoid and myeloid malignancies. Although splenectomy the preferred treatment for symptomatic splenomegaly, it carries significant risks. Radiation therapy (RT) has traditionally been considered palliative option. This study explores use of magnetic resonance guided radiation therapy(MRgRT) splenic irradiation (SI) patients with myelofibrosis (MFI) myelodysplastic/myeloproliferative neoplasms (MDS/MPN).
Pregnancy in women with Sickle Cell Disease (SCD) is a high-risk situation, especially during the third trimester of gestation and post-partum period, due to chronic hypoxia vaso-occlusive phenomena occurring maternal-fetal microcirculation: as result, unfavorable outcomes, such intra-uterine growth restriction, prematurity or fetal loss are more frequent SCD pregnancies. Therefore, there consensus on need for strict multidisciplinary follow-up within specialized structures. Transfusion...
Abstract Introduction Splenomegaly is a common manifestation in chronic lymphoid and myeloid malignancies. While splenectomy the preferred treatment for symptomatic splenomegaly, it carries significant risks. Radiotherapy (RT) has traditionally been considered palliative option. This study explores use of Magnetic Resonance-Guided (MRgRT) splenic irradiation (SI) patients with myelofibrosis (MFI) myelodysplastic/myeloproliferative neoplasms (MDS/MPN). Methods single-center retrospective...
Background: Ruxolitinib (RUX) use and discontinuation are risk factors for severe COVID-19 death in MPN patients (pts). In pts on RUX therapy, predictors disease survival (OS) to unknown. Aims: The aims of this study were distinguish RUX-treated at higher assess prognostic OS. Methods: We performed a sub-analysis the RUX-MF PV-ARC observational studies that include consecutive adult with myelofibrosis (MF) polycythemia vera (PV), respectively. Overall, 815 MF 172 PV treated outside clinical...